ENOV ENOVIS CORPORATION

Enovis Receives FDA Approval of Patient Specific Instrumentation for STAR® Ankle

Enovis Receives FDA Approval of Patient Specific Instrumentation for STAR® Ankle

The approval of the STAR PSI System marks an impactful milestone by allowing surgeons to provide a personalized pre-operative plan for their total ankle replacement patients

Wilmington, DE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced that the U.S. Food and Drug Administration (FDA) has approved the STAR Patient Specific Instrumentation (STAR PSI System) for use with the Company’s STAR® total ankle replacement system.

“Today is an exciting day for our customers and patients,” said Gary Justak, President of Enovis Foot & Ankle. “We acquired the STAR Ankle just two years ago, and the FDA approval of STAR PSI is just one example of our team’s commitment and investment to taking this best-in-class product to the level it deserves. Surgeons now have leading pre-operative planning and cutting guides, that when paired with years of proven, clinical data, set STAR® Ankle up for a brilliant future.”

The STAR PSI System provides a personalized pre-operative plan for each patient. Surgeons receive and review a 3D visualization of the patient’s ankle joint, including information about any existing implants and/or bone defects, to plan for the total ankle replacement case. The STAR PSI System is utilized with an updated and simplified surgical technique, which has the potential to reduce operative time during total ankle replacement cases.

“I’m excited about the Enovis addition of PSI technology which will have great benefit to STAR patients by providing personalized cutting guides and accurate implant sizing to match their unique anatomy,” said Dr. Gregory Lundeeni, a foot and ankle orthopedic surgeon based in Reno, Nevada. “Surgeons will be able to take advantage of the improved precision and efficiency of STAR’s patient specific cut guides.”

The product is entering Early Product Surveillance in December with plans to fully launch by the end of March 2023.

The STAR PSI System is one of several new products introduced by Enovis Foot & Ankle this year. Enovis’ growing foot and ankle portfolio features other new solutions such as the DynaNail Helix™, Arsenal Ankle® Plating System and now the STAR PSI System— all designed to improve patient outcomes.



About Enovis

Enovis Corporation (NYSE: ENOV) is an innovation-driven, medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit .

MK-22-0312 Rev 0



iDr. Lundeen is a paid consultant of Enovis.



Attachment



Katie Sweet
Vice President, Corporate Communications
 
 
EN
01/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENOVIS CORPORATION

 PRESS RELEASE

Enovis to Participate in Upcoming Investor Conferences

Enovis to Participate in Upcoming Investor Conferences Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13th at 8:30 a.m. Eastern Time.Wells Fargo Healthcare Conference on Wednesday, September 3rd at 2:15 p.m. Eastern Time.Baird 2025 Global Healthcare Conference on Wednesday, September 10th at 3:10 p.m. Eastern Time. A link to the l...

 PRESS RELEASE

Enovis Announces Second Quarter 2025 Results

Enovis Announces Second Quarter 2025 Results Continued commercial momentum with second-quarter sales growth of 7% on a reported basisSecond-quarter Reconstructive sales grew 11% year-over-year on a reported basis  Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Second Quarter 2...

 PRESS RELEASE

Enovis to Host Second Quarter 2025 Results Conference Call on August 7...

Enovis to Host Second Quarter 2025 Results Conference Call on August 7th Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at . Conference C...

 PRESS RELEASE

Enovis to Participate in Upcoming Investor Conferences

Enovis to Participate in Upcoming Investor Conferences Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Goldman Sachs 46th Annual Global Healthcare Conference: Ben Berry, Chief Financial Officer, will participate in a fireside chat on Tuesday, June 10th at 2:00 p.m. Eastern Time.Citizens Medical Devices and Healthcare Services Forum: Ben Berry, Chief Financial Officer, will participate in investor meet...

 PRESS RELEASE

Enovis Announces First Quarter 2025 Results

Enovis Announces First Quarter 2025 Results Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch